
IndraLab
Statements
Dapagliflozin inhibits NLRP3. 14 / 14
|
2
12
reach
"Results of our study indicated that SGLT2 inhibitors dapagliflozin can attenuate the formation of atherosclerotic lesion and increase the stability of lesion by inhibiting the NLRP3 inflammasome in diabetic atherosclerosis, which provide further evidence for its benefits in DM patients"